Immunogenicity and Safety of Human Papillomavirus (HPV)-16/18 AS04-Adjuvanted Vaccine in Healthy Boys Aged 10-18 Years

Journal of Adolescent Health

Volumn 44, Issue 1, 2009, Pages 33-40

  Petäjä, Tiina ^a   Keränen, Heli ^a   Karppa, Tiina ^b   Kawa, Anna ^a   Lantela, Sirkku ^a   Siitari Mattila, Mari ^a   Levänen, Helena ^c   Tocklin, Tuomas ^a   Godeaux, Olivier ^d   Lehtinen, Matti ^a   Dubin, Gary ^e  

^a UNIVERSITY OF TAMPERE   (Finland)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^c Health Centre of Mikkeli   (Finland)

^d GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^e GLAXOSMITHKLINE   (United States)

Author keywords

Adolescent; Cervical cancer; Human papillomavirus; Immunogenicity; Male; Vaccine

Indexed keywords

RECOMBINANT HEPATITIS B VACCINE; VIRUS ANTIBODY; WART VIRUS VACCINE;

ADOLESCENT; ADULT; ARTHRALGIA; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE PAIN; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; MALE; MYALGIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RASH; SCHOOL CHILD; SEROCONVERSION; SINGLE BLIND PROCEDURE; URTICARIA;

ADOLESCENT; CHILD; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; MALE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES;

EID: 57649198020     PISSN: 1054139X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jadohealth.2008.10.002     Document Type: Article

References (30)

1. Wallin K.L., Wiklund F., Angström T., et al. Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N Engl J Med 341 (1999) 1633-1638
2. Dillner J., Lehtinen M., Björge T., et al. Prospective seroepidemiologic study of human papillomavirus infection as a risk factor for invasive cervical cancer. J Natl Cancer Inst 89 (1997) 1293-1299
3. Lehtinen M., Dillner J., Knekt P., et al. Serologically diagnosed infection with human papillomavirus type 16 and risk for subsequent development of cervical carcinoma: nested case-control study. BMJ 312 (1996) 537-539
4. Mork J., Lie A.-K., Glattre E., et al. Human papillomavirus as a risk factor for squamous-cell carcinoma of the head and neck cancer. N Engl J Med 344 (2001) 1125-1131
5. Bjørge T., Engeland A., Luostarinen T., et al. Human papillomavirus infection as a risk factor for anal and perianal cancer in a prospective study. Br J Cancer 87 (2002) 61-64
6. Walboomers J.M., Jacobs M.V., Manos M.M., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189 (1999) 12-19
7. Shah K.V. Human papillomaviruses and anogenital cancers. N Engl J Med 337 (1997) 1386-1388
8. Parkin D.M., and Bray F. The burden of HPV-related cancers. Vaccine 24 Suppl 3 (2006) S11-S25
9. Brown D.R., Shew M.L., Qadadri B., et al. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. J Infect Dis 191 (2005) 182-192
10. Kahn J.A. Vaccination as a prevention strategy for human papillomavirus-related diseases. J Adolesc Health 37 6 Suppl (2005) S10-S16
11. Moscicki A.B. Impact of HPV infection in adolescent populations. 7. J Adolesc Health 3 6 Suppl (2005) S3-S9
12. Nielson C.M., Flores R., Harris R.B., et al. Human papillomavirus prevalence and type distribution in male anogenital sites and semen. Cancer Epidemiol Biomarkers Prev 16 6 (2007) 1107-1114
13. Collins S., Mazloomzadeh S., Winter H., et al. High incidence of cervical human papillomavirus infection in women during their first sexual relationship. BJOG 109 (2002) 96-98
14. http://www.stakes.fi
15. Krüger Kjaer S., Munk C., Falck Winther J., et al. Acquisition and persistence of human papillomavirus infection in younger men: a prospective follow-up study among Danish soldiers. Cancer Epidemiol Biomarkers Prev 14 (2005) 1528-1533
16. The Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356 (2007) 1915-1927
17. Paavonen J., Jenkins D., Bosch F.X., et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369 (2007) 2161-2170
18. Descamps D., Hardt K., Spiessens B., et al. Safety of human papillomavirus (HPV)-16/18 AS04 adjuvanted vaccine for cervical cancer prevention: integrated summary of 11 clinical trials. 26th Annual Meeting of the European Society for Pediatric Infectious Diseases (ESPID). May 13-16 (2008), Graz, Austria
19. Harper D.M., Franco E.L., Wheeler C.M., et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367 (2006) 1247-1255
20. Harper D., Gall S., Naud P., et al. Sustained immunogenicity and high efficacy against HPV-16/18 related cervical neoplasia: Long-term follow up through 6.4 years in women vaccinated with Cervarix™ (GSK's HPV 16/18 AS04 candidate vaccine). Gynecol Oncol 109 (2008) 158
21. French K.M., Barnabas R.V., Lehtinen M., et al. Strategies for the introduction of human papillomavirus vaccination: modelling the optimum age- and sex-specific pattern of vaccination in Finland. Br J Cancer 96 (2007) 514-518
22. Kim J.J., Andres-Beck B., and Goldie S.J. The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting. Br J Cancer 97 (2007) 1322-1328
23. Pedersen C., Petaja T., Strauss G., et al. Immunization of early adolescent women with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health 40 (2007) 564-571
24. Harper D.M., Franco E.L., Wheeler C., et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364 (2004) 1757-1765
25. Block S.L., Nolan T., Sattler C., et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 118 (2006) 2135-2145
26. Frampton J.E., and Keating G.M. Reduced-antigen, combined diphtheria, tetanus, and acellular pertussis vaccine (Boostrix™). A review of its use as a single-dose booster immunization. Biodrugs 20 (2006) 371-389
27. Giannini S.L., Hanon E., Moris P., et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 24 (2006) 5937-5949
28. Burchell A.N., Richardson H., Mahmud S.M., et al. Modeling the sexual transmissibility of human papillomavirus infection using stochastic computer simulation and empirical data from a cohort study young women in Montreal, Canada. Am J Epidemiol 163 (2006) 534-543
29. Elbasha E.H., Dasbach E.J., and Insinga R.P. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 13 (2007) 28-41
30. Barnabas R.V., Laukkanen P., Koskela P., et al. Epidemiology of HPV-16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. PLoS Med 3 (2006) e138